Title |
Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data
|
---|---|
Published in |
AIDS Research and Therapy, January 2015
|
DOI | 10.1186/s12981-014-0041-8 |
Pubmed ID | |
Authors |
Christoph D Spinner, Florian Wille, Christiane Schwerdtfeger, Philipp Thies, Ursula Tanase, Guido Von Figura, Roland M Schmid, Werner J Heinz, Hartwig Hf Klinker |
Abstract |
While HIV, AIDS and atypical Mycobacterium infections are closely linked, the use of Integrase-Inhibitor based cART, notably raltegravir-based regimens is more widespread. RAL should be double-dosed to 800 mg semi-daily in situation of rifampicin co-medication, because RAL is more rapidly metabolized due to rifampicin-induced Uridine-5'-diphosph- gluronosyl-transferase (UGT1A1). Recently, it was speculated that chewed RAL might lead to increased absorption, which might compensate the inductive effect of rifampicin-rapid metabolized RAL, as part of cost-saving effects in countries with high-tuberculosis prevalence and less economic power. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 40% |
Egypt | 1 | 20% |
United Kingdom | 1 | 20% |
Unknown | 1 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 4% |
Brazil | 1 | 4% |
Unknown | 22 | 92% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 21% |
Researcher | 4 | 17% |
Student > Doctoral Student | 2 | 8% |
Other | 2 | 8% |
Lecturer | 2 | 8% |
Other | 6 | 25% |
Unknown | 3 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 42% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
Social Sciences | 2 | 8% |
Environmental Science | 1 | 4% |
Immunology and Microbiology | 1 | 4% |
Other | 3 | 13% |
Unknown | 5 | 21% |